David F. McDermott, MD
Advertisement
Articles by David F. McDermott, MD
Advertisement
Latest Updated Articles
Dr. McDermott on Long-Term Benefit With Nivolumab in RCCPublished: July 12th 2016 | Updated:
Dr. David F. McDermott on Nivolumab in RCCPublished: August 5th 2016 | Updated:
Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCCPublished: September 7th 2016 | Updated:
Dr. McDermott on VEGF Plus PD-1 in Renal Cell CarcinomaPublished: January 14th 2017 | Updated:
Dr. McDermott on IMmotion150 Trial in RCCPublished: February 22nd 2017 | Updated:
Dr. McDermott on Lessons From the IMmotion150 Trial in RCCPublished: March 8th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5